UCSF experts head to the Society for Neuro-Oncology Annual Meeting

Jennie W. Taylor, MD
Management of Low Grade Gliomas (CME)
10:45-11:20 AM PT

Susan Chang, MD – Moderator
Clinical Trial Design Workshop: Pearls and Pitfalls in Conducting Neuro-Oncology Clinical Trials
10:30-11:30 AM PT

Shawn Hervey-Jumper, MD – Panelist
Clinical Trial Design Workshop: Developing and Leading Neuro-Oncology Clinical Trials Early in Your Career
2:25-3:25 PM PT

Susan Chang, MD
Understanding Neuro-Oncology Journals
11:40 AM-12:00 PM PT

David R. Raleigh, MD, PhD
Tracking Cellular Changes During Treatment of Nervous System Tumors (CME)
8:20-8:40 AM PT

Jennie W. Taylor, MD, MPH
Survival is associated with circulating B-cells and age among oligodendroglioma patients
12:00-12:05 PM PT

Janine M. Lupo, PhD
Advanced Computational and Diagnostic Imaging Methods, Session Chair
Incorporating Metabolic and Physiologic MRI in AI-based Models for Gliomas (CME)
11:10-11:30 AM PT

Harish Vasudevan, MD, PhD
Beyond MEK Inhibition: Targeting NF1 Loss in Nervous System Tumors
11:10-11:30 AM PT

Payal Watchmaker, PhD
Research specialist in the Okada lab
Development of a Transgenic Mouse Model Enabling Comparative Analysis of chimeric antigen receptor (CAR)-Expressing Immune Cell Populations for Cancer Immunotherapy
11:45-11:50 AM PT

Annette Molinaro, PhD
Biostatistics for Clinical Trial Design, Session Chair (CME)
3:45-5:15 PM PT

Mitchel Berger, MD
Rethinking Surgical Strategies in the Modern Era, Session Chair
Is Maximizing Extent of Resection for Gliomas Still Indicated in the Modern Era of Neurosurgical Oncology? (CME)
4:30-4:50 PM PT

Poster Session (7:30-9:30 PM PT)

Minh P. Nguyen
UCSF medical student in the Raleigh lab
Meningioma copy number variant thresholds reveal optimal sizes for gains or losses that predict local freedom from recurrence or overall survival

Nicholas O. Stevers, PhD
Postdoctoral scholar in the Costello lab
A unifying and self-reinforcing mechanism for tumor immortality in TERT promoter mutant cancers

Mikias Negussie
UCSF medical student in the Hervey-Jumper lab
Molecular and functional drivers of activity dependent glioblastoma proliferation

Russell O. Pieper, PhD
Transient suppression of XPO1 activity is sufficient for Selinexor-induced cytotoxicity in glioblastoma cell lines

Sixuan Pan
Graduate student in the Vasudevan and Abate labs
Single-cell functional genomic analysis of pharmacologic responses in NF1 mutant glioblastoma reveals distinct mechanisms of action for MEK and SHP2 inhibition

Youssef Sibih
UCSF medical student in the Hervey-Jumper lab
Examining the influence of neurosurgical oncology provider access on diffuse glioma survival outcomes: a nationwide county-level approach

Darwin Kwok
Graduate student in the Okada and Costello labs

• Tumor-wide neoantigen-specific T-cells infiltrating mutant IDH1 low-grade gliomas and persisting in peripheral blood allow for personalized TCR-based immunotherapies
• Public tumor-wide neoantigens derived from clonal aberrant splicing events drive tumor-specific T-cell responses

Lee H. Chen, PhD
Postdoctoral scholar in the Costello lab
Heterogeneity of insertion/deletion and single nucleotide variation in drivers of lower grade gliomas

Michael C. Oldham, PhD
Clarifying the Molecular Consequences of Oncogenic Mutations through Multiscale and Multiomic Analysis of Individual Tumors

Geno Guerra, PhD
Postdoctoral scholar in the Francis lab
Antibody Reactivity to Varicella Zoster Virus is Associated with Improved Glioma Survival and is Modified by Germline HLA Polymorphisms

Jacob Young, MD
Neurosurgery resident
Systemic neutralization of IL6 sensitizes IDH-wildtype glioblastoma preclinical models to immune checkpoint inhibition

Akane Yamamichi, MD, PhD
Postdoctoral scholar in the Okada lab
Low-intensity pulsed ultrasound enhances CAR T cell therapy by inducing two-way immune cell trafficking – T cell into tumor and myeloid cell into periphery in a syngeneic mouse glioblastoma model

Marco Gallus, PhD
Postdoctoral scholar in the Okada lab

• Low-intensity pulsed ultrasound promotes the presentation of brain-derived antigens through enhanced trafficking of antigen-presenting cells from the brain into the periphery
• Low-intensity pulsed ultrasound conducts antigen-independent T cell homing into the brain parenchyma with the intact blood-brain barrier

Calixto-Hope Lucas, MD
Postdoctoral scholar in the Solomon lab (now Assistant Professor at Johns Hopkins)
Longitudinal molecular evolution of IDH-wildtype glioblastoma in adults

Jasleen Kaur
Hervey-Jumper lab manager
Comparative analysis of glioma induced impairment models

Mia Salans, MD
Radiation oncology resident
Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: implications of radiographic uncertainty

Yan Li, MD, PhD
In vivo Metabolic Profiling for Recurrent Glioma

Pavithra Viswanath, PhD
Leveraging metabolic vulnerabilities induced by TERT expression for glioblastoma therapy in vivo

Nikita Choudhary
Medical student fellow in the Aghi lab
Multi-omic screening of invasive GBM cells in engineered biomaterials and patient biopsies reveals targetable transsulfuration pathway alterations

Isha Mondal
Junior specialist in the Lu lab
PP2A-inhibition induces STING-Type I-mediated immunologic cell death in GBM

Dace Hines
Power to the patients: a framework for a peer-led AYA virtual support group( view PDF here)

Joanna Phillips, MD, PhD
The molecular and spatial architecture of an immune-rich glioma subtype

Nancy Ann Oberheim Bush, MD, PhD and Christina Weyer Jamora, PhD
Survivorship session moderators
7:15-8:45 AM PT

Gray Umbach, MD
Neurosurgery resident
Pathology specific, pharmacologically reversible loss of neuronal function in human gliomas
7:35-7:45 AM PT

Andy G.S. Daniel, PhD
Postdoctoral scholar in the Hervey-Jumper lab
Glioblastoma-neuronal circuit integration is modulated by interleukin-6
7:55-8:05 AM PT

Hideho Okada, MD, PhD
Redirecting immunosuppressive glioma microenvironment through pharmacological intervention targeting neuronal activity
8:15-:8:20 AM PT

David Solomon, MD, PhD
Molecular Pathology - Diagnosis, Abstract Session Moderator

John Liu, MD, PhD
In vivo perturb-seq defines biological drivers and therapeutic vulnerabilities underlying radiotherapy resistance in glioblastoma
10:45-10:55 AM PT

Geno Guerra, PhD
Postdoctoral scholar in the Francis lab
Longitudinal immune profiles of lower grade adult glioma patients
12:05-12:10 PM PT

Abraham Dada
UCSF medical student in the Hervey-Jumper lab
High glioma proliferation significantly correlates with language deficits regardless of MRI lesion subtype
10:55-11:05 AM PT

Kristi I. Brandes
Graduate student in the Hervey-Jumper lab
Testing and validation of a diffuse glioma cognitive reserve model
11:45-11:50 AM PT

Susan Chang, MD
Provider-Patient Communication in the Digital Age, Session Chair (CME)
10:45 AM -12:15 PM PT
RANO, Session Co-chair
3:45-5:15 PM PT

Meeki Lad
UCSF medical student in the Aghi lab
Skull-derived myeloid cells augment T cell responses and suppress glioblastoma growth
9:20-9:30 AM PT

Sixuan Pan
Graduate student in the Vasudevan and Abate labs
Multiplatform molecular and functional genomic analyses of NF1 mutant glioblastoma identify distinct co-mutation patterns and druggable dependencies underlying selumetinib response
9:30-9:35 AM PT

David Solomon, MD, PhD
“De novo replication repair deficient glioblastoma, IDH-wildtype” is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade
9:35-9:40 AM PT

Rongze Olivia Lu, PhD
Basic Science Session moderator
10:15-11:45 AM PT

John Liu, MD, PhD
CRISPRoff epigenome editing and functional genomics define mediators of chemotherapy resistance in glioblastoma
10:25-10:35 AM PT

Alexander Haddad, MD
Neurosurgery resident
Local delivery of an IL-15 superagonist using a replicating retrovirus syngerizes with temozolomide to increase lymphocyte infiltration and survival in two poorly immunogenic glioblastoma mouse models
10:55-11:05 AM PT

Sabine Mueller, MD, PhD
A Combination Therapy Trial using an Adaptive Platform Design for patients with Diffuse Midline Gliomas (DMGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
10:15-10:25 AM PT

Hideho Okada, MD, PhD
Immunotherapy for CNS Cancer, Session Chair
10:15-11:45 AM PT

Shawn Hervey-Jumper, MD
Therapeutic Implications of Diffuse Glioma Remodeling of Neural Circuits in the Human Brain (CME)
11:20-11:40 AM PT